已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

医学 安慰剂 临床终点 傍晚 内科学 外科 代理终结点 临床试验 意向治疗分析 随机对照试验 病理 天文 物理 替代医学
作者
William D. Tap,Hans Gelderblom,Emanuela Palmerini,Jayesh Desai,Sebastian Bauer,Jean‐Yves Blay,Thierry Alcindor,Kristen N. Ganjoo,Javier Martín‐Broto,Christopher W. Ryan,David M. Thomas,Charles Peterfy,John H. Healey,Michiel A. J. van de Sande,Heather L. Gelhorn,Dale E. Shuster,Qiang Wang,Antoine Yver,Henry H. Hsu,Paul Lin
出处
期刊:The Lancet [Elsevier BV]
卷期号:394 (10197): 478-487 被引量:474
标识
DOI:10.1016/s0140-6736(19)30764-0
摘要

Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, especially in cases that are not amenable to surgical resection.This phase 3 randomised trial had two parts. Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group. Individuals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400 mg morning; 600 mg evening) for the first 2 weeks, followed by 800 mg per day (400 mg twice a day) for 22 weeks. Part two was an open-label study of pexidartinib for all patients. The primary endpoint, assessed in all intention-to-treat patients, was overall response at week 25, and was centrally reviewed by RECIST, version 1.1. Safety was analysed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02371369.Between May 11, 2015, and Sept 30, 2016, of 174 patients assessed for eligibility, 120 patients were randomly assigned to, and received, pexidartinib (n=61) or placebo (n=59). There were 11 dropouts in the placebo group and nine in the pexidartinib group. Emergence of mixed or cholestatic hepatotoxicity caused the data monitoring committee to stop enrolment six patients short of target. The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; absolute difference 39% [95% CI 27-53]; p<0·0001). Serious adverse events occurred in eight (13%) of 61 patients in the pexidartinib group and one (2%) of 59 patients in the placebo group. Hair colour changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (25%) were the most frequent pexidartinib-associated adverse events. Three patients given pexidartinib had aminotransferase elevations three or more times the upper limit of normal with total bilirubin and alkaline phosphatase two or more times the upper limit of normal indicative of mixed or cholestatic hepatotoxicity, one lasting 7 months and confirmed by biopsy.Pexidartinib is the first systemic therapy to show a robust tumour response in TGCT with improved patient symptoms and functional outcomes; mixed or cholestatic hepatotoxicity is an identified risk. Pexidartinib could be considered as a potential treatment for TGCT associated with severe morbidity or functional limitations in cases not amenable to improvement with surgery.Daiichi Sankyo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
满怀完成签到,获得积分10
1秒前
曾经的溪流完成签到,获得积分10
2秒前
小二郎的应助被研友_Z6Qrbn采纳,获得10
3秒前
mmmm发布了新的文献求助10
6秒前
soso完成签到 ,获得积分10
7秒前
7秒前
王木木完成签到 ,获得积分10
8秒前
小李新人发布了新的文献求助10
8秒前
ket的应助被一颗柿子树采纳,获得30
8秒前
sortie完成签到,获得积分10
11秒前
曹大壮完成签到,获得积分10
14秒前
林余发布了新的文献求助10
14秒前
露稚完成签到 ,获得积分10
14秒前
lzp完成签到 ,获得积分10
17秒前
王胜楠发布了新的文献求助10
19秒前
小巧念露完成签到,获得积分10
22秒前
土书完成签到,获得积分10
22秒前
23秒前
彭于晏的应助被科研通管家采纳,获得10
24秒前
笙笙的应助被科研通管家采纳,获得10
24秒前
斯文败类的应助被科研通管家采纳,获得10
25秒前
25秒前
万能图书馆的应助被上善若水采纳,获得10
25秒前
笙笙的应助被科研通管家采纳,获得10
25秒前
汉堡包的应助被科研通管家采纳,获得10
25秒前
田様的应助被科研通管家采纳,获得10
25秒前
ffff完成签到 ,获得积分10
29秒前
兰高锋发布了新的文献求助30
29秒前
温暖无招完成签到 ,获得积分10
33秒前
17完成签到,获得积分10
33秒前
贪玩千儿完成签到,获得积分10
35秒前
liza发布了新的文献求助10
39秒前
爆米花的应助被YCLING采纳,获得10
39秒前
JamesPei的应助被wjw采纳,获得30
43秒前
nanfeng完成签到 ,获得积分10
46秒前
陶醉成协完成签到,获得积分10
46秒前
隐形曼青的应助被刻苦乐天采纳,获得10
46秒前
黎明深雪完成签到 ,获得积分10
48秒前
鲅鱼饺子完成签到 ,获得积分10
49秒前
热情的水杯完成签到,获得积分10
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082